- Home
- CLLS vs NPCE Comparison
CLLS vs NPCE Comparison
Compare CLLS & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLLS | NPCE |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.0M | 328.8M |
| IPO Year | 2007 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CLLS | NPCE |
|---|---|---|
| Price | $4.39 | $16.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $8.00 | ★ $18.00 |
| AVG Volume (30 Days) | 132.4K | ★ 247.9K |
| Earning Date | 11-07-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $82,551,000.00 | ★ $94,864,000.00 |
| Revenue This Year | $32.58 | $24.82 |
| Revenue Next Year | N/A | $1.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 129.04 | 24.08 |
| 52 Week Low | $1.10 | $7.56 |
| 52 Week High | $5.48 | $18.98 |
Technical Indicators
Market Signals| Indicator | CLLS | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 49.34 | 64.01 |
| Support Level | $4.47 | $15.42 |
| Resistance Level | $5.45 | $16.94 |
| Average True Range (ATR) | 0.30 | 0.72 |
| MACD | -0.12 | -0.21 |
| Stochastic Oscillator | 31.17 | 71.67 |
Price Performance
Historical ComparisonAbout CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.